Electrophysiological characterization of BRL-32872 in canine Purkinje fiber and ventricular muscleEffect on early after-depolarizations and repolarization dispersion

European Journal of Pharmacology

Volumn 383, Issue 2, 1999, Pages 215-222

  Faivre, Jean François ^a   Forest, Marie Claire ^a   Gout, Bernard ^a   Bril, Antoine ^a  

^a SmithKline Beecham Laboratoires P   (France)

Author keywords

Antiarrhythmic; Ca2+ channel antagonist; Class III; Clofilium; E 4031; K+ channel antagonist; Proarrhythmic profile

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOFILIUM; N (3,4 DIMETHOXYPHENYL) N [3 [N [2 (3,4 DIMETHOXYPHENYL)ETHYL] N METHYLAMINO]PROPYL] 4 NITROBENZAMIDE; POTASSIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISPERSION; DOG; DRUG ANTAGONISM; FEMALE; HEART DEPOLARIZATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART VENTRICLE WALL; MALE; NONHUMAN; PRIORITY JOURNAL; PURKINJE FIBER;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BENZAMIDES; DOGS; ELECTROPHYSIOLOGY; FEMALE; HEART; HEART VENTRICLES; KINETICS; MALE; PIPERIDINES; POTASSIUM CHANNEL BLOCKERS; PURKINJE FIBERS; PYRIDINES; QUATERNARY AMMONIUM COMPOUNDS;

EID: 0032714445     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00614-7     Document Type: Article

References (36)

1. Abrahamsson C., Duker G., Lundberg C., Carlsson L. Electrophysiological and inotropic effects of H 234/09 (almokalant) in vitro: a comparison with two other novel IK blocking drugs. UK-68,798 (dofetilide) and E-4031. Cardiovasc. Res. 27:1993;861-867.
2. Antzelevitch C., Sicouri S., Lukas A., Di Diego J.M., Nesterenko V.V., Liu D.W., Roubache J.F., Zygmunt A.C., Zhang Z.Q., Iodice A. Clinical implications of electrical heterogeneity in the heart: the electrophysiology and pharmacology of epicardial, M, and endocardial cells. Podrid P.J., Kowey P.R. Cardiac Arrhythmias: Mechanisms, Diagnosis and Management. 1995;88-107 Williams and Wilkins, Baltimore.
3. Anyukhovsky E.P., Sosunov E.A., Rosen M.R. Electrophysiologic effects of nibentan (HE-11) on canine cardiac tissue. J. Pharmacol. Exp. Ther. 280:1997;1137-1146.
4. Banyasz T., Magyar J., Varro A., Kovacs A., Gyonos I., Szenasi G., Nanasi P.P. EGIS-7229, the new combined class III antiarrhythmic agent lack of EAD inducing effect. Gen. Pharmacol. 32:1999;329-333.
5. Black S.C., Chi L., Mu D.X., Lucchesi B.R. The antifibrillatory actions of UK-68,798, a class III antiarrhythmic agent. J. Pharmacol. Exp. Ther. 258:1991;416-423.
6. Bril A. Novel antiarrhythmic agents: from specific pharmacological tools to compounds with multiple cellular activity. Pharmacol. Rev. Comm. 8:1996;9-17.
7. Bril A., Faivre J.F., Forest M.C., Cheval B., Gout B., Linee P., Ruffolo R.R. Jr., Poyser R.H. Electrophysiological effect of BRL 32872, a novel antiarrhythmic agent with potassium and calcium channel blocking properties, in guinea-pig cardiac isolated preparations. J. Pharmacol. Exp. Ther. 273:1995;1264-1272.
8. Bril A., Gout B., Bonhomme M., Landais L., Faivre J.F., Linee P., Poyser R.H., Ruffolo R.R. Jr. Combined potassium and calcium channel blocking activities as the basis for antiarrhythmic properties with low proarrhythmic risk: experimental antiarrhythmic effect of BRL-32872. J. Pharmacol. Exp. Ther. 276:1996;637-646.
9. Bril A., Faivre J.F., Gout B. Combined potassium and calcium channel antagonism for anti-arrhythmic therapy. Ion Channel Modulators. 2:1997;189-194.
10. Bril A., Forest M.C., Cheval B., Faivre J.F. Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: comparison between BRL-32872 and azimilide. Cardiovasc. Res. 37:1998;130-140.
11. Buchanan L.V., Kabell G., Brunden M.N., Gibson J.K. Comparative Assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J. Cardiovasc. Pharmacol. 22:1993a;540-549.
12. Buchanan L.V., Turcotte U.M., Kabell G.G., Gibson J.K. Antiarrhythmic and electrophysiologic effects of ibutilide in a chronic canine model of atrial flutter. J. Cardiovasc. Pharmacol. 22:1993b;10-14.
13. Chi L., Mu D.X., Lucchesi B.R. Electrophysiology and antiarrhythmic actions of E-4031 in the experimental animal model of sudden coronary death. J. Cardiovasc. Pharmacol. 17:1991;285-295.
14. Faivre J.F., Rouanet S., Bril A. Comparative effects of glibenclamide, tedisamil, dofetilide, E-4031 and BRL-32872 on protein kinase A-activated chloride current in guinea-pig ventricular myocytes. J. Cardiovasc. Pharmacol. 31:1998;551-557.
15. Friedrichs G.S., Chi L., Gralinski M.R., Black S.C., Basler G.C., Mu D.X., Pewitt S.R., Johnson C.R., Lucchesi B.R. MS-551 protects against ventricular fibrillation in a chronic canine model of sudden cardiac death. J. Cardiovasc. Pharmacol. 25:1995;314-323.
16. Gough W.B., El-Sherif N. The differential response of normal and ischaemic Purkinje fibres to clofilium, d-sotalol and bretylium. Cardiovasc. Res. 23:1989;554-559.
17. Gout B., Nichols A.J., Feuerstein G.Z., Bril A. Antifibrillatory effects of BRL-32872 in anesthetised Yucatan minipigs with regional ischemia. J. Cardiovasc. Pharmacol. 26:1995;636-644.
18. Gwilt M., Arrowsmith J.E., Blackburn K.J., Burges R.A., Cross P.E., Dalrymple H.W., Higgins A.J. UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J. Pharmacol. Exp. Ther. 256:1991;318-324.
19. Hohnloser S.H., Singh B.N. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J. Cardiovasc. Electrophysiol. 6:1995;920-936.
20. Hondeghem L.M., Snyders D.J. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation. 81:1990;686-690.
21. Katoh H., Ogawa S., Furuno I., Sato Y., Yoh S., Saeki K., Nakamura Y. Electrophysiologic effects of E-4031, a class III antiarrhythmic agent, on re-entrant ventricular arrhythmias in a canine 7-day-old myocardial infarction model. J. Pharmacol. Exp. Ther. 253:1990;1077-1082.
22. Kosar E., Sharma P., Likittanasombat K., Krittayaphong R., Granett J., Egan J., Singh B.N., Nademanee K. Electrophysiologic and hemodynamic effects of a new combined class III and class IV antiarrhythmic agent: BRL 32872A. Pac. Clin. Electrophys. 20:1997;1142. Abstract.
23. Kuo C.S., Munakata K., Reddy C.P., Surawicz B. Characteristics and possible mechanism of ventricular arrhythmias dependent on the dispersion of action potential durations. Circulation. 67:1983;1356-1367.
24. Kuo C.S., Reddy C.P., Munakata K., Surawicz B. Mechanism of ventricular arrhythmias caused by increased dispersion of repolarization. Eur. Heart J. 6:1985;63-70.
25. Kupersmith J., Hoff P. Occurrence and transmission of localized repolarization abnormalities in vitro. J. Am. Coll. Cardiol. 6:1985;152-160.
26. Lathrop D.A. Electromechanical characterization of the effects of racemic sotalol and its optical isomers on isolated canine ventricular trabecular muscle and Purkinje strands. Can. J. Physiol. Pharmacol. 63:1985;1506-1512.
27. Lazzara R. Antiarrhythmic drugs and torsade de pointe. Eur. Heart J. 14:1993;88-92.
28. Lazzara R. From first class to third class: recent upheaval in antiarrhythmic therapy-lessons from clinical trials. Am. J. Cardiol. 78:1996;28-33.
29. Li T., Carr A.A., Dage R.C. Effects of MDL 11,939 on action potential and contractile force in cardiac tissues: a comparison with bretylium, clofilium, and sotalol. J. Cardiovasc. Pharmacol. 16:1990;917-923.
30. Ludbrook J. Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc. Res. 28:1994;303-311.
31. Roden D.M. Early after-depolarizations and torsade de pointe: implications for the control of cardiac arrhythmias by prolonging repolarization. Eur. Heart J. 14:1993;56-61.
32. Roden D.M. Ionic mechanisms for prolongation of refractoriness and their proarrhythmic and antiarrhythmic correlates. Am. J. Cardiol. 78:1996;12-16.
33. + current. Differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol. 96:1990;195-215.
34. Singh B.N. Amiodarone: pharmacological, electrophysiological, and clinical profile of an unusual antiarrhythmic compound. Singh B.N., Wellens H.J.J., Hiraoka M. Electropharmacological Control of Cardiac Arrhythmias. To Delay Conduction or to Prolong Refractoriness? 1994;497-522 Futura Publishing, New York.
35. Surawicz B. Electrophysiologic substrate of Torsade de Pointes: dispersion of repolarization or early afterdepolarizations? J. Am. Coll. Cardiol. 14:1989;172-184.
36. Zuanetti G., Corr P.B. Antiarrhythmic efficacy of a new class III agent, UK-68,798, during chronic myocardial infarction: evaluation using three-dimensional mapping. J. Pharmacol. Exp. Ther. 256:1991;325-334.